AUTOMATIC STOP ORDERS

ORAL ANTICOAGULANTS—
AFTER 24 HOURS
ALBUMIN—
LARGE VOLUME INTRAVENOUS—
INJECTABLE ANTICOAGULANTS (SC)—
CONTROLLED SUBSTANCES—
AFTER 5 DAYS
CORTISONE PRODUCTS—
AFTER 5 DAYS

Date of	Hour of Order	Nurse's Signature	NURSE: PLEASE X IN COLUMN ON LINE, FOR MEDICATIONS REQUIRED FROM PHARMACY PHYSICIAN MUST ENTER DATE, HOUR, AND SIGN EACH SET OF ORDERS.
			ALLERGIES:
			INITIAL ORDERS FOR HEART FAILURE
			(Check appropriate boxes and fill in the blanks)
			1. Admit to Dr 's Service
			☐ Regular Floor ☐ Telemetry ☐ CCU ☐ Other:
			Diagnosis: Heart Failure Code Status: □ Full Code □ DNR or Partial DNR – see DNR Order Sheet
			3. Laboratory Tests: ☐ All preliminary lab tests and studies done in ETD (if not order on separate page) ☐ If initial troponin done, recycle O8hr X 2. Call PMD if results are positive.
			4. ☐ Echocardiogram Reason: ☐ Heart Failure ☐ Other
			or ☐ Pt has recent Echo, please call 2310 and place on chart
			or ☐ Patient's most recent Ejection Fraction%
			6. Activity: 🔾 Per CareMap® 🔾 Other:
			7. Diet: 🗅 2Gm Nat, low cholesterol 🗅 Calorie ADA diet
			☐ Refer to Registered Dietician when pt on unit ☐ Restrict fluids to mL in 24hrs
			8. 🗆 Insert IV: 🗀 Solution: Rate: mL/hr 🗀 Saline Lock
			9. Vital signs: ☐ Per CareMap® ☐ Other:
			☐ Monitor pulse oxymetry every shift and PRN
			☐ Daily weights ☐ Strict intake/output ☐ Insert Foley Catheter
			10. Medications (include name, dose, frequency and route of administration): □ O₂ (check one): □ Nasal cannula ② L/min □ FiO₂ by mask □ Nitroglycerin ointment to chest wall inch(es) ② hold for B/P 90/syst
			 □ Nesiritide (Natrecor) 1.5 mg in 250 mL D₅W □ hold for B/P ≤ 90/syst □ Bolus 2mcg / kg= mL (use dosing table), withdraw bolus from the infusion bag and administer IV push over 60 seconds □ Infusion rate ≠ 0.01 mcg / kg / min = mL / hr (use dosing table)
			ETD Attending Signature:
			Attending Physician Signature:
			These orders are good for 8 hours only unless countersigned by the primary care physician
78			

New 6/17/03

PLEASE DO NOT RETURN CHARTS WITH NEW ORDERS TO RACK-FLAG CHART

DO NOT WRITE IN THIS AREA

THIS SPACE IS FOR PHARMACY

AUTOMATIC STOP ORDERS

ORAL ANTICOAGULANTS— AFTER 24 HOURS
ALBUMIN— AFTER 24 HOURS

LARGE VOLUME INTRAVENOUS— AFTER 24 HOURS

INJECTABLE ANTICOAGULANTS (SC)— AFTER 5 DAYS

CONTROLLED SUBSTANCES— AFTER 5 DAYS

CORTISONE PRODUCTS— AFTER 5 DAYS

MD Date of Order	Hour of Order	Nurse's Signature	T	NURSE: PLEASE X IN COLUMN ON LINE, FOR MEDICATIONS REQUIRED FROM PHARMACY PHYSICIAN MUST ENTER DATE, HOUR, AND SIGN EACH SET OF ORDERS.
				ALLERGIES:
				INITIAL ORDERS FOR HEART FAILURE
				(Check appropriate boxes and fill in the blanks)
				11. Medications continued (include name, dose, frequency and route of administration):
				□ ACE Inhibitor
			7	□ Angiotensin Receptor Blocker
				□ Aspirin
				□ Beta blocker
				□ Digoxin
				Diuretic
				☐ Spironolactone 12.5 mg PO qd or ☐ Warfarin
				U vvariarin
				12. If Patient Develops Chest Pain:
				□ Call Admitting Physician STAT
				□ STAT ECG, give Nitroglycerin 1/150 SL _Q /5 min x 3 if systolic BP/>100mmHg
			,	13. ⊠ Notify Heart Failure team of patient's admission X5770
				14. Additional orders:
				The state of the s
	-			
		'		
				4
				ETD Attending Signature:
			-	Attending Physician Signature:
78				These orders are good for 8 hours only unless countersigned by the primary care physician
. 0				, , , , , , , , , , , , , , , , , , , ,


PLEASE DO NOT RETURN CHARTS WITH NEW ORDERS TO RACK-FLAG CHART

EVIDENCE BASED MANAGEMENT OF ACUTE HEART FAILURE

Robert Berkowitz M.D., Ph.D., FACC; Sidney Glasofer B.S.E, MS (IV)



Early identification of heart failure and risk stratification in the emergency room using clinical assessment and BNP assay



- Heart failure likely
- Clinical assessment should guide decision between admission vs. short term IV diuresis in ER
- Outpatient work-up if previously undiagnosed heart failure

STABILIZATION OF PATIENT

- > Treatment should begin within one hour of ER arrival with IV vasoactive therapy and aggressive IV diuretics^c
- If Cardiogenic shock is present, consider invasive monitoring and inotropic therapy^d

INPATIENT THERAPY AND FURTHER DIAGONOSTIC WORK-UP

- Continued IV therapy with a diuretic and a vasoactive medication
 - Monitor daily weights, electrolytes, BUN, Cr
- ACE inhibitor titration; consider low dose aldactone (class IIIB-IV); consider digoxin^d
- DVT prophylaxis^d, e.g. enoxaparin 40 mg SO OD
- Address co-morbidities; e.g. anemia, diabetes, HTN, hyperlipidemia
- Poor response to IV therapy within first 48 hours indicates need for hemodynamic monitoring; patients refractory to treatment may need long term inotropic therapy, LVAD, or cardiac transplantation
- Determination of etiology of heart failure: Echocardiogram, Ischemic work-up, metabolic evaluatione

EUVOLEMIA (Goal – Day 3)

- Once euvolemia is achieved, consider obtaining a baseline BNP
- Begin Beta-blocker therapy^d
- Consider Bi-ventricular pacing and/or Implantable Cardiac Defibrillator in the appropriate patient^f
- > Transition remaining IV medications to PO
- Patient education: low Na+ diet, smoking cessation, exercise, daily weight monitoring

DISCHARGE PLANNING AND FOLLOW UP

- Referral for heart failure home care or tele-monitoring^g
- > Follow up with doctor in 2-4 weeks
- Monitoring of patient with homecare heart failure nurse or tele-monitoring^g
- Monitor BNP levels in future, rise of BNP to greater than 50% above baseline constitutes decompensated heart failure
- For patients with frequent readmissions associated with chronically decompensated heart failure, outpatient intermittent nesiritide therapy is recommended^d

^{*}For discussion of the strategies presented in this flow chart refer to addendum a-g.

DIURETIC ALGORITHM

Volume overload is the most common presentation of CHF.¹ Loop diuretics in significant amounts antagonize the RAAS, increase the SVR, decrease the GFR and decrease CO²,³ A furosemide drip preceded by a moderate bolus is more effective than IV push lasix and facilitates a continuous diuresis. ³ There is no rebound effect as occurs with IV push lasix alone. ²,³

In contrast, loop diuretics with vasodilator treatment increase urine output, GFR, CO^{4, 5} and when the vasodilator is nesiritide, neurohormonal blockade is obtained. ^{5,6}. Nesiritide is synergistic with loop diuretics requiring less lasix over time⁵ and facilitating renal protection ⁶ leading to improved creatinine.

Nesiritide with furosemide is recommended for CHF treatment. "Patients who received an vasoactive agent earlier in their treatment had a significantly shorter LOS." It is not necessary to down-titrate beta-blockers when beginning vasoactive therapy.

Recommendations for Acute Decompensated Heart Failure in the ETD

On Admission:

Treat within 1-2 hours with:

Nesiritide 2mcg/kg bolus followed by infusion at 0.01 mcg/kg/min to be titrated as needed (by addition of .005mcg/kg/min q 3 hours PRN).

*The higher doses may be required in cases where hypertension exists. The usual duration of treatment with Nesiritide is for 24-72 hours depending on the severity of volume overload).

Concomitant treatment with furosemide:

- Give 40-80 mg IVP furosemide followed by infusion of furosemide 250mg/250mL at 10mg/hour for moderate fluid overload or 15mg/hour for severe/extreme volume overload.
- Goal is to achieve urine output of ≥ 1mL/kg/h (about 600mL per shift). If goal is not achieved in 4 hours, increase furosemide drip by 5mg//h to a maximum of 20mg/hr until adequate diuresis is seen. Monitor urine output every hour and every shift. Maintain diuresis until fluid retention is resolved.

Day 2

• Consider decreasing furosemide drip as patient approaches euvolemia. *This may occur quicker in patients with diastolic verses systolic dysfunction.

Day 3

Transition to PO furosemide when euvolemic:

40 mg QD to BID or 80 mg AM, 40 mg PM QD depending on degree of initial volume overload.

* Avoid Zaroxolyn as possible.

* Note: ACEI titration can begin immediately.

Beta-blockers initiated when patient euvolemic.

Legend

RAAS- Renin Angiotensin Aldosterone System

SVR- Systemic Vascular Resistance

GFR- Glomerular Filtration Rate

CO- Cardiac Output

References

- (1) Kubo SH, Clark M, Laragh JH, et al. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effects of upright posture and diuretics. American Journal of Cardiol. 1987;60:1322-1328.
- (2) Francis GS, Seigel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide with chronic congestive heart failure. Annals of Internal Med. July 1985; 103:1-6.
- (3) Dormans TP, Van Meyel JM, Gerlag GG, Tan Y, Russel GM, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: Bolus injection versus continuous infusion. JACC Aug 1996; 376-382
- (4) Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesintide, a natriuretic peptide, in the treatment of decompensated heart failure. N engl J Med. 2000; 343:246--253
- (5) Mills R, Hobbs R, How to use nesiritide in treating decompensated heart failure. Cleveland Clinic Journal of Medicine. March 2002; 69:3 252-256
- (6) Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure
- (7) Emerman Cl, Peacock WF, Fonarow, GC. Effect of emergency department initiation of vasoactive infusion therapy on heart failure length of stay. Abstract. 2002. American College of Emergency Physicians Scientific Assembly. Seattle, WA.